Phase 1 N=22 CVN058 Effect on Mismatch Negativity in Schizophrenics
Schizophrenia
Primary: Mean Amplitude of Duration of Auditory Mismatch Negativity (MMN) by Dose Level — -0.551; -0.749; -0.386; -1.084 microvolts
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=12 A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.
Healthy
Primary: Maximum Observed Concentration (Cmax) of PF-07817883 — 4030; 4985 ng/mL
Phase 1 N=36 A Study of Donanemab (LY3002813) in Healthy Chinese Participants
Healthy
Primary: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to…
Phase 1 N=42 A Study of Donanemab (LY3002813) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Four Weeks (AUC[0-4 Weeks]) of Donanemab (i.e) Period 2, Period 4, Period 6…
Phase 1 N=46 EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Rhabdoid Tumors · INI1-negative Tumors · Synovial Sarcoma
Primary: Recommended Phase 2 Dose (RP2D) (Dose Escalation Only) — 1200; 520 mg/m^2 BID
Phase 1 N=12 A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease
Huntingtons Disease
Primary: Concentrations of RO7234292 in CSF (Cerebrospinal Fluid) — 197000; 372000; 933000; 6220 ng/mL
Phase 1 N=70 A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
Ovarian Cancer · Breast Cancer
Primary: Maximum Plasma Concentration During the Dosing Interval at Steady State (CmaxSS) — 10395.085; 9676.278 ng/mL
Phase 1 N=30 Study of Efficacy and Safety of ABO809 in Healthy Participants
Cryptosporidium Infection, Cryptosporidiosis
Primary: Percentage of Participants With Cryptosporidium Infection From 72 Hours to 10 Days Post ABO809 Oral Administration — 50; 57.1; 60.0 percentage of participants
Phase 1 N=63 Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)
Schizophrenia
Primary: Part 1 & 2: Number of Participants Who Experienced an Adverse Event (AE) — 4; 9; 3; 2 Participants
Phase 1 N=52 A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers
Biological Availability
Primary: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Zavegepant — 83.65; 102.5; 184.4; 47.29 Hours*nanograms per milliliter (h*ng/mL)
Phase 1 N=20 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC24) of PF-06882961 10 mg Single Dose on Day 1 — 287.4 nanogram*hour per milliter (ng*hr/mL)
Phase 1 N=18 A Study to Learn How the Study Medicine (Ponsegromab) is Changed and Eliminated From Healthy Chinese Adults
Healthy
Primary: Area Under the Serum Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Unbound and Total Ponsegromab — 109000; 590200; 350300; 1105000…
Phase 1 N=86 Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders
Pneumococcal Infections
Primary: Immune Responses — 1.95; 1.69; 1.22; 0.78 ug/mL
Phase 1 N=19 CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension
Ocular Hypertension · Open Angle Glaucoma
Primary: Ocular Treatment Emergent Adverse Events — 9; 7; 9; 1 Number of Treatment-Emergent Events
Phase 1 N=28 Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents
Myelodysplastic Syndrome
Primary: Maximum Tolerated Dose of Entinostat Given in Combination With Pembrolizumab — 1; 2 Participants